Christopher Bowlus
Staff Affiliate - OtherAbout
Research
Publications
2025
Linerixibat significantly improves cholestatic pruritus in primary biliary cholangitis: results of the pivotal Phase 3 GLISTEN trial
Hirschfield G, Bowlus C, Jones D, Kremer A, Mayo M, Tanaka A, Andreone P, Jia J, Jin Q, Macías-Rodríguez R, Cobitz A, Currie B, Gorey C, Lazic I, Podmore D, Ribeiro A, Shannon J, Swift B, McLaughlin M, Levy C. Linerixibat significantly improves cholestatic pruritus in primary biliary cholangitis: results of the pivotal Phase 3 GLISTEN trial. Zeitschrift Für Gastroenterologie 2025, 63: e457-e457. DOI: 10.1055/s-0045-1810779.Peer-Reviewed Original ResearchLong-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis: pooled interim results for up to 3 years from the ASSURE study
Lawitz E, Trivedi P, Kowdley K, Gordon S, Bowlus C, Hurtado M, Hirschfield G, Gulamhusein A, Demir M, Crittenden D, Zhuo S, Heusner C, Levy C. Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis: pooled interim results for up to 3 years from the ASSURE study. Zeitschrift Für Gastroenterologie 2025, 63: e375-e376. DOI: 10.1055/s-0045-1810647.Peer-Reviewed Original ResearchRecompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapy
Chen Y, Wen H, Li Y, Zhang W, Mao T, Jiang C, Zhang H, Zhou Y, Pu X, Li B, Zhang J, Yan L, Lian M, Sheng L, Guo C, Wang Q, Miao Q, Hua J, Li H, Tang R, Bowlus C, Gershwin M, You Z, Xiao X, Ma X. Recompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapy. JHEP Reports 2025, 7: 101496. PMID: 40823171, PMCID: PMC12355535, DOI: 10.1016/j.jhepr.2025.101496.Peer-Reviewed Original ResearchHigher platelet countLow IgG levelsImmunosuppressive therapyDecompensated cirrhosisBilirubin levelsPlatelet countIgG levelsPrognostic significanceAutoimmune hepatitisClinical resolutionSurvival outcomesLong-term prognostic implicationsRisk of liver transplantationTransplant-free survivalAbstractText Label="Background &AbstractText Label="ImpactPrognostic implicationsLiver transplantationAbstractText Label="RESULTS"AbstractText Label="ConclusionsSignificant long term benefitAbstractText Label="MethodsCirrhosisLong-term benefitsPatientsLong-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.
Levy C, Trivedi P, Kowdley K, Gordon S, Bowlus C, Londoño M, Hirschfield G, Gulamhusein A, Lawitz E, Vierling J, Mayo M, Jacobson I, Kremer A, Corpechot C, Jones D, Buggisch P, Zhuo S, Proehl S, Heusner C, McWherter C, Crittenden D. Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. The American Journal Of Gastroenterology 2025 PMID: 40553148, DOI: 10.14309/ajg.0000000000003603.Peer-Reviewed Original ResearchPrimary biliary cholangitisMonths of treatmentNumerical rating scaleLong-term efficacyBiliary cholangitisResponse ratePruritus Numerical Rating ScaleSerious adverse eventsYear of treatmentInterim study resultsComposite response rateInterim cutoffLong-term useOpen-labelPlacebo-ControlledPlacebo-treatedTrial patientsAdverse eventsSeladelparPatientsResponse completenessAssurance studyCholangitisMonthsRating ScalePre‐Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis
Caines A, Lu M, Wu T, Trudeau S, Melkonian C, Gonzalez H, Sahota A, Schmidt M, Daida Y, Bowlus C, Gordon S. Pre‐Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis. Journal Of Gastroenterology And Hepatology 2025, 40: 2209-2218. PMID: 40551359, DOI: 10.1111/jgh.17035.Peer-Reviewed Original ResearchPrimary biliary cholangitisAntimitochondrial antibody positivityAntimitochondrial antibodiesYears prior to diagnosisAMA-positiveNHW patientsBiliary cholangitisDiagnosis of primary biliary cholangitisBlack patientsPrimary biliary cholangitis patientsAlkaline phosphatasePositive antimitochondrial antibodyElevated alkaline phosphataseEvaluate racial differencesPre-DiagnosisAsian American Pacific IslanderPBC patientsAAPI patientsPatient groupALP levelsPatientsDiagnosisNHWCholangitisNon-HispanicP197 Long-term efficacy and safety of open-label seladelpar in primary biliary cholangitis: pooled interim results up to 3 years from ASSURE
Lawitz E, Trivedi P, Kowdley K, Gordon S, Bowlus C, Londoño M, Hirschfield G, Gulamhusein A, Crittenden D, Zhuo S, Heusner C, Levy C. P197 Long-term efficacy and safety of open-label seladelpar in primary biliary cholangitis: pooled interim results up to 3 years from ASSURE. 2025, a205-a205. DOI: 10.1136/gutjnl-2025-bsg.332.Peer-Reviewed Original ResearchP200 Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated cirrhosis in the phase 3 RESPONSE trial
Villamil A, Younes Z, Bowlus C, Vierling J, Vasura A, Galli A, Rabinovitz M, Nevens F, Carroll S, Yang K, Crittenden D, McWherter C, Lawitz E. P200 Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated cirrhosis in the phase 3 RESPONSE trial. 2025, a207-a208. DOI: 10.1136/gutjnl-2025-bsg.335.Peer-Reviewed Original ResearchP201 Impact of elafibranor on markers of disease activity and progression in patients with advanced primary biliary cholangitis
Phagura A, Mayo M, Kowdley K, Bowlus C, Vierling J, Jacobson I, Antunes N, Sleiman M, Touati N, Zein C, Levy C. P201 Impact of elafibranor on markers of disease activity and progression in patients with advanced primary biliary cholangitis. 2025, a208-a209. DOI: 10.1136/gutjnl-2025-bsg.336.Peer-Reviewed Original ResearchP203 Attenuation, near resolution, and prevention of pruritus in patients with primary biliary cholangitis receiving seladelpar: a secondary analysis from RESPONSE
Kremer A, Levy C, Mayo M, Bowlus C, Kowdley K, Hirschfield G, Carroll S, Yang K, Crittenden D, McWherter C. P203 Attenuation, near resolution, and prevention of pruritus in patients with primary biliary cholangitis receiving seladelpar: a secondary analysis from RESPONSE. 2025, a209-a209. DOI: 10.1136/gutjnl-2025-bsg.337.Peer-Reviewed Original ResearchP232 Long-term safety of seladelpar 10 mg with up to 5 years of treatment in patients with primary biliary cholangitis
Trivedi P, Gordon S, Gulamhusein A, Villamil A, Lawitz E, Vierling J, Londoño M, Kremer A, Bowlus C, Proehl S, Zhuo S, Crittenden D, McWherter C. P232 Long-term safety of seladelpar 10 mg with up to 5 years of treatment in patients with primary biliary cholangitis. 2025, a228-a228. DOI: 10.1136/gutjnl-2025-bsg.366.Peer-Reviewed Original Research